Combination therapy for cancer treatment
AssigneeTakeda Pharmaceutical Company Limited
InventorsAkihiro OHASHI, Kenichi IWAI, Tadahiro NAMBU, Jie YU, Kurt ENG, Michael Joseph KURANDA
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the treatment of cancer using a combination therapy comprising Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof, and one or more PARP inhibitors. Compound I.
Claims46
A tablet comprising Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof
- and a compressible filler.
The tablet of any one of claims 1-11, further comprising from about 0.25 wt % to about 2 wt % of a binder. The tablet of claim 12, wherein the binder is polyvinylpyrrolidone.
A tablet comprising an intra-granular component and an extra-granular component, wherein the intra-granular component comprises Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof
- and an intra-granular compressible filler.
A tablet comprising:
- from about 10 wt % to about 30 wt % of Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof
- from about 3 wt % to about 10 wt % of silicified microcrystalline cellulose,
- from about 5 wt % to about 20 wt % of mannitol.
- from about 0.25 wt % to about 2 wt % of polyvinylpyrrolidone,
- from about 25 wt % to about 80 wt % of anhydrous lactose,
- from about 2 wt % to about 3 wt % of crosearmellose sodium, and
- from about 1 wt % to about 2 wt % of magnesium stearate.
A tablet comprising an intra-granular component and an e, iia-granularcomponent, whereine i a- granular component comprises:
- from about 40 wt % to about 60 wt % of Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof
- from about 20 wt % of silicified microcrystalline cellulose,
- from about 20 wt % to about 40 wt % of mannitol,
- from about 1 wt % to about 3 wt % of polyvinylpyrrolidone,
- from about 1 wt % to about 3 wt % of croscarmellose sodium. and
- from about 0.5 wt % to about 2 wt % of magnesium stearate, and
- wherein the extra-granular component comprises:
- from about 90 wt % to about 98 wt % of anhydrous lactose,
- from about 2 wt % to about 5 wt % of croscarmellose sodium, and
- from about 1 wt % to about 3 wt % of magnesium stearate.
A tablet comprising:
- Compound 1 and/or tautomers thereof or a pharmaceutically
- 12.5 wt %
- acceptable salt or hydrate thereof
- Compound 1
- Mannitol
- 7.5 wt %
- Silicified microcrystalline cellulose
- 3.75 wt %
- Polyvinylpyrrolidone
- 0.5 wt %
- Croscarmellose sodium
- 2.5 wt %
- Magnesium stearate
- 1.25 wt %
- Anhydrous lactose
- 72 wt %
A tablet comprising:
- Compound 1 and/or tautomers thereof or a pharmaceutically
- 25 wt %
- acceptable salt or hydrate thereof
- Compound 1
- Mannitol
- 15 wt %
- Silicified microcrystalline cellulose
- 7.5 wt %
- Polyvinylpyrrolidone
- 1 wt %
- Croscarmellose sodium
- 3 wt %
- Magnesium stearate
- 1.5 wt %
- Anhydrous lactose
- 47 wt %
Dependencies are inferred from the claim text.